Monument Therapeutics is a spin out from Cambridge Cognition advancing small molecules paired with a digital biomarker through phase I clinical trials, to address significant challenges in central nervous system (CNS) drug discovery.

Neuroscience has the potential to be in the ’20s what oncology has been in the last decade
Status | Active |
Website | https://monumenttx.com/ |
Category | Biotech |
Modality | Small Molecule |
Therapeutics Area | Neurosciences |
Headquaters | Cambridge, UK |
Investment Portfolio | Fund Investment |
Co-Investors | Catapult Ventures, Cambridge Angels and Meltwind |